Anti|VEGF agents in metastatic colorectal cancer

Anti-VEGF agents in metastatic colorectal cancer (mCRC)

The goal of the current review was to identify comparative preclinical data for the currently available VEGF-targeted therapies.

Anti-vascular endothelial growth factor receptor in colorectal cancer

In recent years, the treatment of metastatic colorectal cancer (mCRC) has dramatically changed thanks to the advent of new drugs called ...

Optimizing the use of anti VEGF targeted therapies in patients with ...

Colorectal cancer is one of the most frequent forms of cancer both in men and women, and patients with metastatic disease are now being exposed to an ...

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment ...

Therapeutic regimens for metastatic colorectal cancer (mCRC) include chemotherapy and targeted therapy. The chemotherapeutic drugs generally ...

Should we move beyond VEGF inhibition in metastatic colorectal ...

Abstract: Data from recent clinical trials utilizing bevacizumab or other anti-VEGF agents in patients with metastatic colorectal cancer (mCRC) show ...

613P Effect of prior use of anti-VEGF agents on overall survival in ...

Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III ...

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Muhammad Wasif Saif GI Oncology Program, Tufts University ...

Future Directions in Vascular Endothelial Growth Factor–Targeted ...

Bevacizumab, the first approved vascular endothelial growth factor (VEGF)–targeted agent for metastatic colorectal cancer, continues to be developed in ...

Mechanisms of adverse effects of anti-VEGF therapy for cancer

Three drugs, bevacizumab (Avastin®), sunitinib malate (Sutent®, SU11248), and sorafenib (Nexavar®, BAY 43-9006) that were developed for ...

[PDF] Anti-VEGF agents in metastatic colorectal cancer (mCRC)

Two preclinical studies were identified that compared bevacizumab and the newer agent, aflibercept, and identified some important differences in binding and ...

Sequencing of Antiangiogenic Agents in the Treatment of Metastatic ...

Based on the results of E3200, bevacizumab is presently recommended in the National Comprehensive Cancer Network guidelines as second-line ...

Ramucirumab, another anti-angiogenic agent for metastatic ...

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice · Abstract.

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the ...

Abstract: Significant progression has been achieved in the treatment of metastatic colorectal cancer (mCRC) in recent years. This has been partly attributed ...

Treatment of metastatic colorectal cancer (Beyond the Basics)

Bevacizumab enhances the antitumor effect of other chemotherapy drugs. Bevacizumab is not effective when given by itself, but is generally given ...

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor ...

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to ...

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic ...

Fluoropyrimidines (e.g., fluorouracil and capecitabine), irinotecan, and oxaliplatin are the standard cytotoxic drugs used in treating metastatic colorectal ...

New Ways to Inhibit the VEGF Pathway in Metastatic Colorectal ...

... VEGF Pathway in Metastatic Colorectal Cancer." The goals of this program are to educate clinicians on newly approved and emerging classes of agents that ...

Anti-VEGF agents in metastatic colorectal cancer (mCRC)

PDF | Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the ...

Angiogenesis in metastatic colorectal cancer and the benefits of ...

As mentioned above, bevacizumab and aflibercept are antiangiogenic agents approved for the treatment of mCRC [55, 56]. Other antiangiogenic ...

Anti-VEGF Therapy in Metastatic Colorectal Cancer: Where Are We ...

Ian Chau, MD ... Has received honorarium from: Taiho Pharmaceutical Co., Ltd. Dr Chau does not intend to discuss off-label uses of drugs, mechanical devices, ...